Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.59 |
| ▸ | RAF1 | P04049 | 17/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29272322 | 1.00 | BRAF (0.59) | BRAFRAF1CYP2C9MAPK13KDR | |
| SCHEMBL29272107 | 0.92 | BRAF (0.50) | BRAFRAF1CYP2C9MAPK13KDR | |
| SCHEMBL30236229 | 0.92 | BRAF (0.50) | BRAFRAF1CYP2C9MAPK13KDR | |
| SCHEMBL29272291 | 0.91 | BRAF (0.57) | BRAFRAF1MAPK13KDRMAPK12 | |
| SCHEMBL30236740 | 0.91 | BRAF (0.57) | BRAFRAF1MAPK13KDRMAPK12 | |
| SCHEMBL30237017 | 0.91 | BRAF (0.60) | BRAFRAF1CYP2C9 | |
| SCHEMBL29272226 | 0.91 | BRAF (0.60) | BRAFRAF1CYP2C9 | |
| SCHEMBL30236993 | 0.91 | BRAF (0.51) | BRAFRAF1CYP2C9MAPK13KDR | |
| SCHEMBL29272252 | 0.91 | BRAF (0.51) | BRAFRAF1CYP2C9MAPK13KDR | |
| SCHEMBL29272451 | 0.89 | BRAF (0.58) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | BRAF 569/4885RAF1 1140/4885CYP2C9 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.